Game Changing Innovation in Respiratory Medicine
At OmniSpirant, we believe our technology has the potential to positively impact the lives of millions of patients. We have created a bold new approach to treat currently incurable respiratory diseases that affect hundreds of millions of people worldwide. Our planned pipeline of advanced therapies intersect regenerative medicine and gene therapy in the hope of treating these devastating lung diseases of severely unmet patient need. Our patent pending platform technology (OmniSomes) is based on inhaled bioengineered stem cell exosomes (extracellular vesicles) which are capable of efficient intracellular delivery of a variety of RNA and protein based therapeutic cargoes to effectively treat these diseases at the required level of complexity. Our engineered stem cell exosomes are initially being used to develop first in class regenerative gene therapies for cystic fibrosis (OS001) and lung cancer (OS003). OS003 will be investigated using systemic (intravenous) administration for treating other types of cancer that are believed to be amenable to treatment as they share broadly similar driver mutations. The proprietary mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases (see our pipeline in Technology section). Please browse our site to learn more about our mission and technology.
Mission
Transforming medicine through the development of first-in-class regenerative gene therapies.
Game Changing Innovation in Respiratory Medicine
At OmniSpirant, we believe our technology has the potential to positively impact the lives of millions of patients. We have created a bold new approach to treat currently incurable respiratory diseases that affect hundreds of millions of people worldwide. Our planned pipeline of advanced therapies intersect regenerative medicine and gene therapy in the hope of treating these devastating lung diseases of severely unmet patient need. Our patent pending platform technology (OmniSomes) is based on inhaled bioengineered stem cell exosomes (extracellular vesicles) which are capable of efficient intracellular delivery of a variety of RNA and protein based therapeutic cargoes to effectively treat these diseases at the required level of complexity. Our engineered stem cell exosomes are initially being used to develop first in class regenerative gene therapies for cystic fibrosis (OS001) and lung cancer (OS003). OS003 will be investigated using systemic (intravenous) administration for treating other types of cancer that are believed to be amenable to treatment as they share broadly similar driver mutations. The proprietary mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases (see our pipeline in Technology section). Please browse our site to learn more about our mission and technology.
Mission
Transforming medicine through the development of first-in-class regenerative gene therapies.
A Novel Inhaled Stem Cell Extracellular Vesicle (Exosome) Based Platform Technology
OmniSome Therapeutic Platform
OmniSomes lung targeting technologies offer an exemplar delivery platform for treating respiratory diseases and are the initial focus of the company’s therapeutic pipeline (see below). The first problem to solve for pulmonary gene therapy is that the gene transfer vectors must efficiently reach the lung via aerosol delivery. Our partnership with Aerogen Limited has resulted in optimised OmniSome formulations with their state-of-the art vibrating mesh nebuliser technology – delivering OmniSomes with high efficiency while maintaining the structural integrity and functionality of the EVs.
Trapping of delivery vectors in viscous mucus in the lung is another significant barrier to gene transfer to the underlying target cells. Even if the mucus layer can be penetrated, inefficient penetration through the cell membrane further impedes access of traditional gene therapy vectors to the underlying target cells, thus preventing successful gene transfer. OmniSomes have exhibited mucus diffusion and tropism for cell entry and gene transfer in human lung cell models (air-liquid interface cell cultures) and have been successfully aerosolised in small animal studies to effect in vivo gene transfer.
Adding further complexity is the processing of the carriers inside the cells – EVs are naturally occurring carriers of RNA and other messengers from cell to cell in the body – this gene transfer, refined by millennia of evolution, has demonstrated 30-40 fold more efficient gene transfer than synthetic lipid nanoparticles*.
The benefits of the OmniSome technology are not just related to delivery and efficient gene transfer as they are derived from stem cells which have widely documented therapeutic efficacy – they are thus expected to further benefit patients afflicted by respiratory diseases through anti-inflammatory, anti-fibrotic, anti-microbial, immune cell modulatory and tissue regeneration effects. The stem cells used in research and product development are ethically sourced from healthy, consenting donors (bone-marrow or adipose tissues).
* Murphy DE, de Jong OG, Evers MJW, Nurazizah M, Schiffelers RM, Vader P. Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles. Nano Lett. 2021 Feb 24;21(4):1888-1895. doi: 10.1021/acs.nanolett.1c00094. Epub 2021 Feb 11. PMID: 33570966; PMCID: PMC8023702.
Partnering Opportunities
The properties of OmniSomes are applicable to a wide variety of diseases amenable to gene therapy, targeting other organs in the body (e.g., liver, CNS, digestive and cardiovascular systems).
Feel free to contact us to discuss how OmniSomes could enable the partnered co-development of your RNA therapeutic assets by leveraging our expertise in EV manufacturing and delivery technologies.
